OCT Company, a key player in clinical research for over two decades, has facilitated more than 400 projects involving over 50,000 patients and volunteers. In an exclusive interview with Forbes, Dmitry Evgenievich Sharov, the company’s founder and CEO, shared insights into OСT’s origins, its role as a bridge between Russian and Chinese pharmaceutical manufacturers, and why clinical research transcends mere business—it is a mission where human lives are at stake.
The article highlights the upcoming III Russian-Chinese Pharmaceutical Forum, set to take place in June in Shanghai, where OСT will further strengthen international partnerships. It also delves into OСT’s critical contributions during the pandemic and outlines strategic plans to expand global collaboration while advancing educational initiatives for young professionals in the field.
Discover the full story on
Forbes